



Press release

STADA closes acquisition of Walmark, creating a winning portfolio for Central Europe

- Walmark is a leading consumer healthcare company in Central Europe with a direct presence across nine EU countries and sales in more than 40 countries.
- With this acquisition, STADA will significantly strengthen its market position in Central Europe, broadening its consumer healthcare portfolio.
- STADA CEO Peter Goldschmidt: "With the acquisition of Walmark, we'll create a winning portfolio for Central Europe and further internationalize our business."

Bad Vilbel, March 5, 2020 – STADA Arzneimittel AG announces the closing of the previously announced acquisition of Walmark a.s. from Mid Europa Partners. This acquisition enables STADA to significantly broaden its global Branded Products portfolio with Walmark's unique offering that includes variety of products (vitamins and minerals, children's, women's and men's health, joint care, digestive and intestinal, and cough and cold).

"STADA and Walmark will create a winning portfolio for Central Europe: with STADA's growth strategy and Walmark's strong focus on innovation, we are further internationalising our overall business and strongly pushing towards our main goal – to become a leader in branded consumer health products and generics in Europe," stated STADA CEO, Peter Goldschmidt.

Walmark is a manufacturer of well-established, market-leading consumer health brands in Central Europe. Established in 1990 and headquartered in the Czech Republic, Walmark has a direct presence across nine EU countries, including the Czech Republic, Slovakia, Poland, Hungary, Bulgaria, Romania, Lithuania, Latvia and Estonia, and sells its

Executive Board: Peter Goldschmidt (CEO) / Dr. Wolfgang Ollig / Miguel Pagan Fernandez
Supervisory Board Chairman: Dr. Günter von Au



products to more than 40 countries worldwide. The company employs more than 540 people – around 150 of them at the production site in Trinec in the Czech Republic.

“We look forward to adding Walmark’s high-quality Trinec manufacturing site to our global production network. Furthermore, we are even planning to produce selected STADA products in Trinec, thereby not only taking full advantage of the existing expertise but in addition using the facility’s capacity for supporting our strong volume growth” said STADA’s Chief Technology Officer Miguel Pagan Fernandez.

About STADA Arzneimittel AG

STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The company focuses on a two pillar strategy consisting of generics, including specialty pharmaceuticals and non-prescription consumer health products. Worldwide, STADA Arzneimittel AG sells its products in approximately 120 countries. In financial year 2018, STADA achieved adjusted Group sales of EUR 2,330.8 million and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 503.5 million. As of December 31, 2018, STADA employed 10,416 people worldwide.

Additional information for journalists:

STADA Arzneimittel AG / Media Relations / Stadastrasse 2-18 / 61118 Bad Vilbel – Germany
Phone: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215 / E-Mail: press@stada.de
Or visit us on the Internet at www.stada.com/press

Additional information for capital market participants:

STADA Arzneimittel AG / Investor & Creditor Relations / Stadastrasse 2-18 / 61118 Bad Vilbel – Germany / Phone: +49 (0) 6101 603-4689 / Fax: +49 (0) 6101 603-215 / E-mail: ir@stada.de
Or visit us on the Internet at www.stada.com/investor-relations

Executive Board: Peter Goldschmidt (CEO) / Dr. Wolfgang Ollig / Miguel Pagan Fernandez
Supervisory Board Chairman: Dr. Günter von Au